Medical Ikkou Group (3353) · RiskRestated
Challenges in Ensuring a Stable Supply of Generic Medicines
First written in FY2023-Q1. 3 of 4 entries say "Restated". Latest entry: FY2023.
4entries
2years
0from disclosures
How it moved
Same theme, other companies
Challenges in securing a stable supply system for generic drugsA theme 2 companies write about · 2 as a headwind · 0 as a tailwind
1 other company's latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2023RestatedAnnual report
「In the pharmaceutical wholesaling business, amid challenges in ensuring a stable supply of generic drugs, the company integrated its sub-subsidiary into a core subsidiary in March 2022 and worked to strengthen its sales structure and control expenses.」
The company continues to describe the business environment in which ensuring a stable supply of generic drugs is a challenge, as well as the strengthening of its sales structure and control of expenses through subsidiary integration. - FY2023-Q3RestatedAnnual report
「In the pharmaceutical wholesaling business, amid challenges in ensuring a stable supply of generic drugs」
The company continues to identify ensuring a stable supply of generic drugs as a business challenge. - FY2023-Q2RestatedAnnual report
「In the pharmaceutical wholesaling business, amid challenges in ensuring a stable supply of generic drugs」
The company continues to identify ensuring a stable supply of generic drugs as a business challenge. - FY2023-Q1First statedAnnual report
「Amid challenges in ensuring a stable supply of generic drugs」
The company has explicitly identified ensuring a stable supply of generic drugs as a business challenge for the first time. This filing does not state that a supply shortage or similar issue actually occurred, however.